Previous 10 | Next 10 |
home / stock / crl / crl articles
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Charles River Laboratories International, Inc. (NYSE: CRL)'s Research Model and Services ("RMS") business is seeing extensive growth ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrade...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is conducting a thorough investigation into possible violations of securities l...
SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is conducting a thorough investigation into possible violations of securities l...
PHILADELPHIA, June 13, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Charles River Laboratories Intl. (NYSE:CRL) (...
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is conducting a thorough investigation into possible infractions of federal and ...
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continui...
NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigat...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good...
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract...